We, Aprogen, Inc., are a listed company on the Korea Exchange (007460:KS) with over 20 years of experience in biological R&D and are one of Korea’s foremost biopharmaceutical companies with over 200 R&D and 350 GMP staff.
We have developed multiple and distinctive antibody and receptor engineering technologies that empower novel drug discovery and development. We have also accumulated various knowledge in proprietary cell line development and cell culturing methods that allow us to achieve exceptional productivity of up to 30 times the industry average.
Utilizing these technological innovations, we currently have 7 Biosimilars and 5 Novel Drugs in our pipeline, where all of 12 are waiting for partners to maximize their respective potentials.
We have developed multiple and distinctive antibody and receptor engineering technologies that empower novel drug discovery and development. We have also accumulated various knowledge in proprietary cell line development and cell culturing methods that allow us to achieve exceptional productivity of up to 30 times the industry average.
Utilizing these technological innovations, we currently have 7 Biosimilars and 5 Novel Drugs in our pipeline, where all of 12 are waiting for partners to maximize their respective potentials.
Ticker:
007460:KS
Exchange:
Korean Exchange
Company Type:
Publicly Traded Company
Company Website:
Company HQ State:
Not Provided
Company HQ Country:
Korea - South Korea
Year Founded:
2000
Main Therapeutic Focus:
Multiple Therapeutics
Lead Product in Development:
Herceptin Biosimilar
Development Phase of Primary Product:
Phase III
Number Of Unlicensed Products (For Which You Are Seeking Partners):
12
Speaker
